- 英文名称3,5,7-Trihydroxy-2-(3-Hydroxy-4-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)Phenyl)-4H-Chromen-4-One
- 中文名称绣线菊甙
- IUPAC名称3,5,7-trihydroxy-2-(3-hydroxy-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)-4H-chromen-4-one
- 其它别名3,3′,4′,5,7-Pentahydroxyflavone 4′-Glucoside; Quercetin 4′-O-β-D-Glucopyranoside; 4'-(β-D-Glucopyranosyloxy)-3,5,5',7-Tetrahydroxyflavone; 4'-[(β-D-Glucopyranosyl)Oxy]-3,3',5,7-Tetrahydroxyflavone; Qercetin-4'-O-β-D-Glucoside; Spireoside; 2-(4-(Beta-D-Glucopyranosyloxy)-3-Hydroxyphenyl)-3,5,7-Trihydroxy-4H-1-Benzo; 4H-1-Benzopyran-4-One,2-(4-(Beta-D-Glucopyranosyloxy)-3-Hydroxyphenyl)-3,5,7-T
- CAS编号20229-56-5
- MFCD编号:MFCD00221723
- EINECS号:243-614-6
- FDA UNII编号:K2B74751XI
- 分子式:C21H20O12分子量:464.38
- 产品CID: 1027238
- 产品分类生物化工 → 中草药成分

- 相似结构搜索
- 产品信息参考
;
;
;
;
- InChIKey: OIUBYZLTFSLSBY-HMGRVEAOSA-N
- InChI=1S/C21H20O12/c22-6-13-15(26)17(28)19(30)21(33-13)32-11-2-1-7(3-9(11)24)20-18(29)16(27)14-10(25)4-8(23)5-12(14)31-20/h1-5,13,15,17,19,21-26,28-30H,6H2/t13-,15-,17+,1
- 计算化学: 氢键受体数12.0氢键供体数8.0可旋转键数4.0
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
quercetol 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide UDP-glucose 43H40O16C43H40O16D-Glucose quercetol 📜14-O-β-Lactosyl-Quercetin置于e. Coli β-Galactosidase,Tris Buffer体系中,化学反应 0.5H,以90%的收率获得绣线菊甙
参考文献:一种用于合成黄酮苷的糖合酶催化剂.
标题:一种用于合成黄酮苷的糖合酶催化剂.
摘要:
Doi:10.1002/anie.200604177
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2002165207-A1
优先权日:2001-05-02
标题 :Compositions and methods for the treatment of diabetic neuropathy
发明人:ROSENBLOOM RICHARD
摘要:Compositions and a method for the treatment of diabetic neuropathy is disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.
专利号:US-7914823-B2
优先权日:2000-12-21
标题 :Method and composition for the topical treatment of diabetic neuropathy
发明人:ROSENBLOOM RICHARD ALLEN
权利人:PROPHASE LABS INC
摘要:A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recovery of the damaged nerve tissues.
专利号:US-12036300-B2
优先权日:2021-03-31
标题:Methods and compositions for improving skin
发明人:LIAO I-CHIEN; BRIEVA PATRICIA; JUCHAUX FRANCK; BOUEZ CHARBEL; ZHENG QIAN; QIAN KUN
权利人:OREAL
摘要:A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.
专利号:US-2021317497-A1
优先权日:2018-06-22
标题:Monbretin a (mba) synthesis using a heterologous nucleic acid(s) encoding a mba pathway enzyme
发明人:BOHLMANN CARL JOERG; IRMISCH SANDRA; JO SEOHYUN
权利人:UNIV BRITISH COLUMBIA
摘要:Provided are transgenic organisms, such as plants and plant parts, cells, and related compositions and methods for producing and monitoring the genotype for enhanced production of montbretin A and/or its precursors. For example, provided is a transgenic organism comprising at least one heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes at least one enzyme in a montbretin A (MbA) metabolic pathway. The organisms can be a plant, plant part, or plant cell, or a microorganism such as a yeast. Also provided is a method for producing at least one montbretin A (MbA) precursor and/or MbA, comprising permitting the expression of the at least one heterologous nucleic acid in the transgenic organism. The disclosure also provides isolated nucleic acid molecules that comprise sequence encoding at least one enzyme in a montbretin A (MbA) metabolic pathway and vectors comprising the nucleic acids.
专利号:RO-137147-A2
优先权日:2021-05-31
标题 :PHYTOTHERAPEUTIC PRODUCT FOR NATURAL STIMULATION OF COLLAGEN SYNTHESIS AND PROCEDURE FOR OBTAINING